DUPUYTREN LITERATURE: MATRIX CONDITIONING

These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Medline Title Search (Dupuytren + (Matrix or ECM))

Selected Publications

• Alfonso-Rodríguez Camilo-Andrés, Garzón Ingrid, Garrido-Gómez Juan, Oliveira Ana-Celeste-Ximenes, Martín-Piedra Miguel-Ángel, Scionti Giuseppe, Carriel Víctor, Hernández-Cortés Pedro, Campos Antonio, Alaminos Miguel. (2014). “Identification of Histological Patterns in Clinically Affected and Unaffected Palm Regions in Dupuytren’s Disease.” PLoS ONE 9 (11): e112457. (PDF)
• Augoff Katarzyna, Ratajczak Katarzyna, Gosk Jerzy, Tabola Renata, Rutowski Roman. (2006). “Gelatinase A Activity in Dupuytren’s Disease.” Journal of Hand Surgery 31 (10): 1635–39. (PDF)
• Baird KS, Crossan JF, Ralston SH. (1993). “Abnormal Growth Factor and Cytokine Expression in Dupuytren’s Contracture.” Journal of Clinical Pathology 46 (5): 425–28. (PDF)
• Berndt A, Kosmehl H, Mandel U, Gabler U, Luo Xinmei, Celeda D, Zardi L, Katenkamp D. (1995). “TGFβ and bFGF Synthesis and Localization in Dupuytren’s Disease (Nodular Palmar Fibromatosis) Relative to Cellular Activity, Myofibroblast Phenotype and Oncofetal Variants of Fibronectin.” The Histochemical Journal 27 (12): 1014–20. (PDF)
• Bianchi Enrica, Taurone Samanta, et al. (2015). “Involvement of pro-Inflammatory Cytokines and Growth Factors in the Pathogenesis of Dupuytren’s Contracture: A Novel Target for a Possible Future Therapeutic Strategy?” Clinical Science 129 (8): 711–20. (PDF)
• Brandes G, Reale E, Brenner P, Korner T. (1994). “Interactions Between Proteoglycans and Collagen Fibrils in the Palmar Fascia in Dupuytren’s Disease.” In Dupuytren’s Disease Pathobiochemistry and Clinical Management, 16–23. (PDF)
• Bujak Maro, Ratkaj Ivana, Markova-Car Elitza, Jurišić Davor, Horvatić Anita, Vučinić Srđan, Lerga Jonatan, Baus-Lončar Mirela, Pavelić Krešimir, Kraljević Pavelić Sandra. (2015). “Inflammatory Gene Expression Upon TGF-β1-Induced p38 Activation in Primary Dupuytren’s Disease Fibroblasts.” Frontiers in Molecular Biosciences 2 (December): 1–9. (PDF)
• Forrester Helen B, Temple-Smith Peter, Ham Seungmin, de Kretser David, Southwick Graeme, Sprung Carl N. (2013). “Genome-Wide Analysis Using Exon Arrays Demonstrates an Important Role for Expression of Extra-Cellular Matrix, Fibrotic Control and Tissue Remodelling Genes in Dupuytren’s Disease.” PloS One 8 (3): e59056. (PDF)
• Howard Jeffrey C, Varallo Vincenzo M, Ross Douglas C, Roth James H, Faber Kenneth J, Alman Benjamin, Gan Bing Siang. (2003). “Elevated Levels of Beta-Catenin and Fibronectin in Three-Dimensional Collagen Cultures of Dupuytren’s Disease Cells Are Regulated by Tension in Vitro.” BMC Musculoskeletal Disorders 4 (July): 16. (PDF)
• Huang Chenyu, Ogawa Rei. (2012). “Fibroproliferative Disorders and Their Mechanobiology.” Connective Tissue Research 53 (3): 187–96. (PDF)
• Huang Xiangwei, Yang Naiheng, Fiore Vincent F, Barker Thomas H, Sun Yi, Morris Stephan W, Ding Qiang, Thannickal Victor J, Zhou Yong. (2012). “Matrix Stiffness-Induced Myofibroblast Differentiation Is Mediated by Intrinsic Mechanotransduction.” American Journal of Respiratory Cell and Molecular Biology 47 (3): 340–48. (PDF)
• Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. (2007). “A Complete Expression Profile of Matrix-Degrading Metalloproteinases in Dupuytren’s Disease.” J Hand Surg Am 32 (3): 51–343. (PDF)
• Kosmehl H, Berndt A, Katenkamp D, Mandel U, Bohle R, Gabler U, Celeda D. (1995). “Differential Expression of Fibronectin Splice Variants, Oncofetal Glycosylated Fibronectin and Laminin Isoforms in Nodular Palmar Fibromatosis.” Pathol Res Pract 191 (11): 1105–13. (PDF)
• Koźma EM, Olczyk Krystyna, Wisowski Grzegorz, Glowacki A, Bobinski R, Koźma Ewa Maria, Głowacki Andrzej, Bobiński Rafał. (2005). “Alterations in the Extracellular Matrix Proteoglycan Profile in Dupuytren’s Contracture Affect the Palmar Fascia.” J Biochem 137 (4): 463–76. (PDF)
• Koźma Ewa M, Wisowski Grzegorz, Kusz Damian, Olczyk Krystyna, Kozma EM. (2011). “The Role of Decorin and Biglycan Dermatan Sulfate Chain(s) in Fibrosis-Affected Fascia.” Glycobiology 21 (10): 1301–16. (PDF)
• Koźma Ewa M, Wisowski Grzegorz, Olczyk Krystyna, Kozma EM. (2009). “Platelet Derived Growth Factor BB Is a Ligand for Dermatan Sulfate Chain(s) of Small Matrix Proteoglycans from Normal and Fibrosis Affected Fascia.” Biochimie 91 (11–12): 1394–1404. (PDF)
• Magro G, Lanzafame S, Micali G. (1995). “Co-Ordinate Expression of Alpha 5 Beta 1 Integrin and Fibronectin in Dupuytren’s Disease.” Acta Histochem 97 (3): 229–33. (PDF)
• Gorman David BO. (2017). “The Extracellular Matrix in Dupuytren Disease.” In P.M.N. Werker et Al. (Eds.), Dupuytren Disease and Related Diseases – The Cutting Edge, DOI 10.1007/978-3-319-32199-8_6, 43–54. (PDF)
• Ratajczak-Wielgomas Katarzyna, Gosk Jerzy, Rabczyński Jerzy, Augoff Katarzyna, Podhorska-Okołów Marzenna, Gamian Andrzej, Rutowski Roman. (2012). “Expression of MMP-2, TIMP-2, TGF-β1, and Decorin in Dupuytren’s Contracture.” Connective Tissue Research 53 (6): 469–77. (PDF)
• Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. (2009). “The Role of an MMP Inhibitor in the Regulation of Mechanical Tension by Dupuytren’s Disease Fibroblasts.” The Journal of Hand Surgery, European Volume 34 (6): 783–87. (PDF)
• Townley William A, Cambrey Alison D, Khaw Peng T, Grobbelaar Adriaan O. (2008). “Matrix Metalloproteinase Inhibition Reduces Contraction by Dupuytren Fibroblasts.” Journal of Hand Surgery 33 (9): 1608–16. (PDF)
• Tripoli Massimiliano, Cordova Adriana, Moschella Francesco. (2016). “Update on the Role of Molecular Factors and Fibroblasts in the Pathogenesis of Dupuytren ’ S Disease.” Journal of Cell Communication and Signaling, no. 1971. Journal of Cell Communication and Signaling. (PDF)
• Ulrich Dietmar, Ulrich Franziska, Piatkowski Andrzej, Pallua Norbert. (2009). “Expression of Matrix Metalloproteinases and Their Inhibitors in Cords and Nodules of Patients with Dupuytren’s Disease.” Archives of Orthopaedic and Trauma Surgery 129 (11): 1453–59. (PDF)
• Ulrich D, Hrynyschyn K, Pallua N. (2003). “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Sera and Tissue of Patients with Dupuytren’s Disease.” Plast Reconstr Surg 112 (5): 1279–86. (PDF)
• Varallo Vincenzo M, Gan Bing Siang, Seney Shannon, Ross Douglas C, Roth James H, Richards Robert S, McFarlane Robert M, Alman Benjamin, Howard Jeffrey C. (2003). “Beta-Catenin Expression in Dupuytren’s Disease: Potential Role for Cell-Matrix Interactions in Modulating Beta-Catenin Levels in Vivo and in Vitro.” Oncogene 22 (24): 3680–84. (PDF)
• Vi Linda, Feng Lucy, Zhu Rebecca D, Wu Yan, Satish Latha, Gan Bing Siang, O’Gorman David B. (2009). “Periostin Differentially Induces Proliferation, Contraction and Apoptosis of Primary Dupuytren’s Disease and Adjacent Palmar Fascia Cells.” Experimental Cell Research 315 (20): 3574–86. (PDF)
• Wilkinson Janine M, Davidson Rose K, Swingler Tracey E, Jones Eleanor R, Corps Anthony N, Johnston Phillip, Riley Graham P, Chojnowski Adrian J, Clark Ian M. (2012). “MMP-14 and MMP-2 Are Key Metalloproteases in Dupuytren’s Disease Fibroblast-Mediated Contraction.” Biochimica et Biophysica Acta 1822 (6). Elsevier B.V.: 897–905. (PDF)